Feb 10 (Reuters) - Ocean Biomedical OCEA.O:
OCEAN BIOMEDICAL ANNOUNCES BREAKTHROUGH FINDINGS IN EGFR-MUTANT LUNG CANCER AND PLANS FOR FDA ALIGNMENT ON NEXT-STAGE DEVELOPMENT
OCEAN BIOMEDICAL- TO INITIATE PRECLINICAL STUDIES TO ADVANCE IMMUNOTHERAPY PROGRAM & TO ENGAGE WITH FDA FOR FIRST-IN-HUMAN TRIALS
Source text: ID:nGNX9fMqJF
Further company coverage: OCEA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.